Introduction: We assessed the clinical outcome and survival of 70 patients with primary vaginal squamous cell carcinoma undergoing radiotherapy (RT) at the Divisions of Radiotherapy, University of Pisa and ASST Cremona between January 1995 and June 2016. Methods: 58 patients received external beam RT (EBRT) to the entire vagina, para-vaginal area and pelvic nodes (total dose: 45-50.4 Gy). 29 patients (41.4%) received concomitant weekly cisplatin 40 mg/m2. 35 patients received an additional (15-36 Gy) high-dose-rate (HDR) brachytherapy (BT) boost and 13 received an additional (9-25 Gy) EBRT boost to the primary tumor site. 12 women exclusively received HDR-BT up to a total dose of (30-58 Gy). Results: Median overall survival (OS) was 85 months. A total RT dose of > 60 Gy was significantly associated with a better OS (p = 0.015). There was a trend for a better OS for patients aged < 70 years and for those undergoing EBRT to the entire vagina and pelvis plus BT boost. The most common grade 1-2 acute toxicities were diarrhea (24.1%) and cystitis (20.7%); grade 3 cystitis only occurred in 2 patients (3.4%). Conclusions: EBRT followed by BT boost seems to be the best treatment for vaginal carcinoma. The total dose of RT should be > 60 Gy.

Journal Section:
Original Article
Keywords:
Vaginal carcinoma, External beam radiation, Brachytherapy, Chemotherapy, Recurrence
1.
Hacker NF, Eifel PJ, Van der Velden J: Cancer of the vagina. Int J Gynaecol Obstet 2015;131(Suppl 2):S84-S87.
2.
Siegel RL, Miller KD, Jemal A: Cancer statistics 2016. CA Cancer J Clin 2016;66:7-30.
3.
Gao G, Smith DI: Human papillomavirus and the development of different cancers. Cytogenet Genome Res 2016;150:185-193.
4.
Wu X, Matanoski G, Chen VW, et al.: Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States. Cancer 2008;113(Suppl):2873-2882.
5.
Hiniker SM, Roux A, Murphy JD, et al.: Primary squamous cell carcinoma of the vagina: Prognostic factors, treatment patterns, and outcomes. Gynecol Oncol 2013;131:380-385.
6.
Kirkbride P, Fyles A, Rawlings GA, et al.: Carcinoma of the vagina-experience at the Princess Margaret Hospital (1974-1989). Gynecol Oncol 1995;56:435-443.
7.
Chang JH, Jang WI, Kim YB, et al.: Definitive treatment of primary vaginal cancer with radiotherapy: Multi-institutional retrospective study of the Korean Radiation Oncology Group (KROG 12-09). J Gynecol Oncol 2016;27:e17.
8.
Frank SJ, Jhingran A, Levenback C, Eifel PJ: Definitive radiation therapy for squamous cell carcinoma of the vagina. Int J Radiat Oncol Biol Phys 2005;62:138-147.
9.
Perez CA, Grigsby PW, Garipagaoglu M, et al.: Factors affecting long-term outcome of irradiation in carcinoma of the vagina. Int J Radiat Oncol Biol Phys 1999;44:37-45.
10.
De Crevoisier R, Sanfilippo N, Gerbaulet A, et al.: Exclusive radiotherapy for primary squamous cell carcinoma of the vagina. Radiother Oncol 2007;85:362-370.
11.
Lian J, Dundas G, Carlone M, et al.: Twenty-year review of radiotherapy for vaginal cancer: An institutional experience. Gynecol Oncol 2008;111:298-306.
12.
Nonaka T, Nakayama Y, Mizoguchi N, et al.: Definitive radiation therapy for invasive carcinoma of the vagina: Impact of high-dose-rate intracavitary brachytherapy. Int J Clin Oncol 2013;18:314-320.
13.
Gadducci A, Fabrini MG, Lanfredini N, Sergiampietri C: Squamous cell carcinoma of the vagina: Natural history, treatment modalities and prognostic factors. Crit Rev Oncol Hematol 2015;93:211-224.
14.
Dalrymple JL, Russell AH, Lee SW, et al.: Chemoradiation for primary invasive squamous carcinoma of the vagina. Int J Gynecol Cancer 2004;14:110-117.
15.
Samant R, Lau B, Tam T: Primary vaginal cancer treated with concurrent chemoradiation using cis-platinum. Int J Radiat Oncol Biol Phys 2007;69:746-750.
16.
Nashiro T, Yagi C, Hirakawa M, et al.: Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: Case series and literature review. Int J Clin Oncol 2008;13:335-339.
17.
Sinha B, Stehman F, Schilder J, et al.: Indiana University experience in the management of vaginal cancer. Int J Gynecol Cancer 2009;19:686-693.
18.
Beller U, Benedet JL, Creasman WT, et al.: Carcinoma of the vagina. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95(Suppl 1):S29-S42.
19.
CTCAE v4.0:NIH Publication No.09-5410.
20.
Kucera H, Vavra N: Radiation management of primary carcinoma of the vagina: Clinical and histopathological variables associated with survival. Gynecol Oncol 1999;40:12-16.
21.
Lee WR, Marcus RB Jr, Sombeck MD, et al.: Radiotherapy alone for carcinoma of the vagina: The importance of overall treatment time. Int J Radiat Oncol Biol Phys 1994;29:983-988.
22.
Tran PT, Su Z, Lee P, et al.: Prognostic factors for outcomes and complications for primary squamous cell carcinoma of the vagina treated with radiation. Gynecol Oncol 2007;105:641-649.
23.
Di Donato V, Bellati F, Fischetti M, et al.: Vaginal cancer. Crit Rev Oncol Hematol 2012;81:286-295.
24.
Laliscia C, Fabrini MG, Delishaj D, et al.: Concomitant external beam irradiation and chemotherapy followed by high dose rate brachytherapy boost in the treatment of squamous cell carcinoma of the vagina: A single-center retrospective study. Anticancer Res 2016;36:1885-1890.
25.
Miyamoto DT, Viswanathan AN: Concurrent chemoradiation for vaginal cancer. PLoS One 2013;8:e65048.
26.
Prameela CG, Ravind R, Gurram BC, et al.: Prognostic factors in primary vaginal cancer: A single institute experience and review of literature. J Obstet Gynaecol India 2016;66:363-371.
27.
Ghia AJ, Gonzalez VJ, Tward JD, et al.: Primary vaginal cancer and chemoradiotherapy: A pattern-of-care analysis. Int J Gynecol Cancer 2011;21:378-384.
28.
Blecharz P, Reinfuss M, Ryś J, et al.: Radiotherapy for carcinoma of the vagina. Immunocytochemical and cytofluorometric analysis of prognostic factors. Strahlenther Onkol 2013;189:394-400.
29.
Hellman K, Lundell M, Silfverswärd C, et al.: Clinical and histopathologic factors related to prognosis in primary squamous cell carcinoma of the vagina. Int J Gynecol Cancer 2016;16:1201-1211.
30.
Shah CA, Goff BA, Lowe K, et al.: Factors affecting risk of mortality in women with vaginal cancer. Obstet Gynecol 2009;113:1038-1045.
© 2017 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.